title: Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
abstract: BACKGROUND
  Oral mucositis (OM) is a common complication of conditioning regimens with high-dose melphalan (HDmel). This retrospective cohort study analyzes the impact of oral cryotherapy (OC) or room temperature saline rinses on the prevention of OM in patients with multiple myeloma (MM) or lymphoid neoplasias submitted to autologous stem cell transplantation (ASCT) in a single center.
  
  
  METHODS
  From August 2006 to July 2011, 134 consecutive patients were enrolled. Two consecutive groups were included: Non-OC (August 2006 to April 2009, 68 patients) and OC (May 2009 to July 2011, 66 cases). MM cases (78, 58%) received HDmel as the conditioning regimen and 56 patients (42%) with lymphoma received BEAM.
  
  
  RESULTS
  The non-OC and OC groups were comparable for the main clinicobiologic features and type of neoplasia. OM was more frequent and severe in patients receiving BEAM as the conditioning therapy. The group of OC showed less frequent and less severe mucositis and fewer days on antibiotics. No differences were observed in the duration of OM, need for parenteral nutrition and narcotics, and the length of hospital stay on comparison with the OC and non-OC groups. By multivariate analyses, OC was an independent favorable prognostic factor for OM development.
  
  
  CONCLUSIONS
  This study shows that OC is more effective than saline rinses in the prevention of OM in patients with lymphoma and myeloma receiving conditioning regimens with HDmel for ASCT.
authors.affiliation: Clinical Haematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, José Carreras Research Institute, Badalona, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Batlle
authors.forename: Mireia
authors.initials: M
authors.lastname: Morgades
authors.forename: Susana
authors.initials: S
authors.lastname: Vives
authors.forename: Christelle
authors.initials: C
authors.lastname: Ferrà
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.forename: Juan-Manuel
authors.initials: JM
authors.lastname: Sancho
authors.forename: Blanca
authors.initials: B
authors.lastname: Xicoy
authors.forename: Miriam
authors.initials: M
authors.lastname: Moreno
authors.forename: Laura
authors.initials: L
authors.lastname: Magallón
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Ribera
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007036:Hypothermia, Induced / Q000009:adverse effects / Q000379:methods; D015994:Incidence; D008223:Lymphoma / Q000150:complications* / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D011379:Prognosis; D012189:Retrospective Studies; D013280:Stomatitis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019653:Myeloablative Agonists; D008558:Melphalan
keywords: high-dose melphalan; oral cryotherapy; oral mucositis